Omeprazolo Hikma (Omeprazole Sodium)

Omeprazole, the active ingredient in Omeprazolo Hikma, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and adolescents. GNH USA supplies Omeprazolo Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazolo Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazolo Hikma is a proton pump inhibitor that acts on the gastric acid secretion pathway.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics. - NSAID‑associated ulcer prophylaxis: lowers risk of ulcer formation in high‑risk patients.

Omeprazolo Hikma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Clostridioides difficile infection - Acute interstitial nephritis - Severe allergic reactions (anaphylaxis, angio‑edema) - Low magnesium levels (hypomagnesemia) - Fracture risk with long‑term use - Vitamin B12 deficiency with prolonged therapy

Before initiating Omeprazolo Hikma, consider the following safety points:

- Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term users: watch for bone density loss, magnesium and vitamin B12 levels. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Elderly patients: start at the lowest effective dose and monitor for falls. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazolo Hikma can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, consider alternative therapy. - Atazanavir/ritonavir: markedly decreased antiviral exposure, contraindicated.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Digoxin: increased serum levels, check renal function and drug levels. - Methotrexate (high dose): reduced clearance, monitor for toxicity. - Iron supplements: decreased absorption, separate dosing by at least 2 h.